A randomized open study to compare the efficacy and safety of GLP-1 analogue (Liraglutide) versus DPP-4 inhibitor (Vildagliptin) in patients with Type 2 Diabetes.

A randomized open study to compare the efficacy and safety of GLP-1 analogue (Liraglutide) versus DPP-4 inhibitor (Vildagliptin) in patients with Type 2 Diabetes. - ERA-DM Chapter 2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004953

Enrollment

Registered

2011-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Vildagliptin Liraglutide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetes 2)HbA1c >=6.5% during 8 weeks prior to the study 3)Treated with Sitaglptin only or Sitagliptin and single oral hypoglycemic agent(OHA:SU,BG,TZD) over 12 weeks prior to the study

Exclusion criteria

Exclusion criteria: 1)Hypersensitivity to or contraindication of Liraglutide and Vildagliptin 2)None Type 2 diabetes 3)Medical history and/or complication of Diabetic ketoacidosis 4)Medical history and/or complication of severe hypoglycemia 5)Insulin treatment within 4 weeks prior to the study 6)Treatment with Liraglutide or Vildagliptin within 12 weeks prior to the study 7)New or Change treatment with Glucocorticoid 8)Unstable glycemic contol 9)Ccr(Cockcraft) < 30mL/h or sCre > 2.5 mg/dL(male), > 2.0mg/dL (Female) 10)AST or ALT >=2.5 time of institutional upper normal limit 11)Uncontrolled hypertension(systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg) 12)Severe health problems not suitable for the study 13)Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
HbA1c,Body weight	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026